

Zhenlin Ju

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1195453/publications.pdf>

Version: 2024-02-01

42
papers

4,322
citations

186265

28
h-index

315739

38
g-index

43
all docs

43
docs citations

43
times ranked

9414
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | A pan-cancer proteomic perspective on The Cancer Genome Atlas. <i>Nature Communications</i> , 2014, 5, 3887. | 12.8 | 456 |
| 2 | The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. <i>Cancer Cell</i> , 2015, 28, 515-528. | 16.8 | 426 |
| 3 | PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. <i>Cancer Research</i> , 2019, 79, 311-319. | 0.9 | 404 |
| 4 | ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. <i>Nature Medicine</i> , 2018, 24, 556-562. | 30.7 | 372 |
| 5 | ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. <i>Cancer Discovery</i> , 2015, 5, 752-767. | 9.4 | 361 |
| 6 | BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. <i>Cancer Cell</i> , 2018, 33, 401-416.e8. | 16.8 | 215 |
| 7 | Systematic Functional Annotation of Somatic Mutations in Cancer. <i>Cancer Cell</i> , 2018, 33, 450-462.e10. | 16.8 | 213 |
| 8 | Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. <i>Genome Research</i> , 2012, 22, 2120-2129. | 5.5 | 206 |
| 9 | Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. <i>Cancer Cell</i> , 2017, 31, 225-239. | 16.8 | 190 |
| 10 | Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers. <i>Science Translational Medicine</i> , 2017, 9, . | 12.4 | 174 |
| 11 | Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. <i>Cancer Cell</i> , 2019, 35, 851-867.e7. | 16.8 | 156 |
| 12 | Immuno-genomic landscape of osteosarcoma. <i>Nature Communications</i> , 2020, 11, 1008. | 12.8 | 143 |
| 13 | A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018, 7, 422-437.e7. | 6.2 | 134 |
| 14 | Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors. <i>Cancer Cell</i> , 2014, 26, 479-494. | 16.8 | 73 |
| 15 | Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 5951-5966. | 8.2 | 72 |
| 16 | An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. <i>Proteome Science</i> , 2012, 10, 56. | 1.7 | 59 |
| 17 | Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. <i>Npj Systems Biology and Applications</i> , 2017, 3, 8. | 3.0 | 55 |
| 18 | Essential roles of mitochondrial biogenesis regulator Nrf1 in retinal development and homeostasis. <i>Molecular Neurodegeneration</i> , 2018, 13, 56. | 10.8 | 54 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. <i>British Journal of Cancer</i> , 2020, 122, 405-412. | 6.4 | 53 |
| 20 | Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. <i>Molecular Cancer Research</i> , 2016, 14, 278-286. | 3.4 | 48 |
| 21 | PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. <i>Molecular Oncology</i> , 2015, 9, 1694-1703. | 4.6 | 47 |
| 22 | YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway. <i>Cancer Research</i> , 2017, 77, 1637-1648. | 0.9 | 47 |
| 23 | Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. <i>Nature Communications</i> , 2018, 9, 4583. | 12.8 | 44 |
| 24 | Development of a robust classifier for quality control of reverse-phase protein arrays. <i>Bioinformatics</i> , 2015, 31, 912-918. | 4.1 | 43 |
| 25 | Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. <i>Cancer Cell</i> , 2020, 38, 829-843.e4. | 16.8 | 40 |
| 26 | High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. <i>Clinical Cancer Research</i> , 2016, 22, 5068-5078. | 7.0 | 38 |
| 27 | Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. <i>Cancer Immunology Research</i> , 2020, 8, 1365-1380. | 3.4 | 37 |
| 28 | DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-Like Factor 4 Expression. <i>Clinical Cancer Research</i> , 2017, 23, 5585-5597. | 7.0 | 34 |
| 29 | Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2019, 155, 420-428. | 1.4 | 28 |
| 30 | A Comprehensive Comparison of Normalization Methods for Loading Control and Variance Stabilization of Reverse-Phase Protein Array Data. <i>Cancer Informatics</i> , 2014, 13, CIN.S13329. | 1.9 | 19 |
| 31 | Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. <i>Oncotarget</i> , 2019, 10, 3533-3546. | 1.8 | 19 |
| 32 | Prognostic relevance of acquired uniparental disomy in serous ovarian cancer. <i>Molecular Cancer</i> , 2015, 14, 29. | 19.2 | 15 |
| 33 | A murine preclinical syngeneic transplantation model for breast cancer precision medicine. <i>Science Advances</i> , 2017, 3, e1600957. | 10.3 | 10 |
| 34 | Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1014-1022. | 6.4 | 9 |
| 35 | Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling. <i>British Journal of Cancer</i> , 2021, 124, 1556-1565. | 6.4 | 9 |
| 36 | Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. <i>Oncotarget</i> , 2017, 8, 106989-107001. | 1.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. PLoS ONE, 2020, 15, e0239966. | 2.5 | 4 |
| 38 | Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer. BMC Cancer, 2022, 22, 282. | 2.6 | 3 |
| 39 | Title is missing!. , 2020, 15, e0239966. | | 0 |
| 40 | Title is missing!. , 2020, 15, e0239966. | | 0 |
| 41 | Title is missing!. , 2020, 15, e0239966. | | 0 |
| 42 | Title is missing!. , 2020, 15, e0239966. | | 0 |